{"commentary":{"count":74,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":29,"youtube":28,"podcast":17},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT06211036\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"DeLLphi-305","nct_id":"NCT06211036","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=dellphi-305-nct06211036. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources"},"registry":{"acronym":"DeLLphi-305","arms":[{"description":"Participants will receive tarlatamab once every 2 weeks (Q2W) and durvalumab once every 4 weeks (Q4W).","label":"Tarlatamab in Combination With Durvalumab","type":"EXPERIMENTAL"},{"description":"Participants will receive durvalumab Q4W alone.","label":"Durvalumab Alone","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2028-09-30","type":"ESTIMATED"},"conditions":["Extensive-Stage Small-Cell Lung Cancer","Small-Cell Lung Cancer"],"enrollment":{"count":563,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Tarlatamab","type":"DRUG"},{"name":"Durvalumab","type":"DRUG"}],"last_update":"2025-12-17","lead_sponsor":"Amgen","official_title":"A Phase 3, Open-label, Multicenter, Randomized Study of Tarlatamab in Combination With Durvalumab vs Durvalumab Alone in Subjects With Extensive-Stage Small-Cell Lung Cancer Following Platinum, Etoposide and Durvalumab (DeLLphi-305)","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2027-07-05","type":"ESTIMATED"},"primary_outcomes":[{"measure":"OS","timeFrame":"Up to approximately 3 years"}],"references":[{"citation":"Paulson KG, Lau SCM, Ahn MJ, Moskovitz M, Pogorzelski M, Hafliger S, Parkes A, Zhang Y, Hamidi A, Thompson CG, Wermke M. Safety and activity of tarlatamab in combination with a PD-L1 inhibitor as first-line maintenance therapy after chemo-immunotherapy in patients with extensive-stage small-cell lung cancer (DeLLphi-303): a multicentre, non-randomised, phase 1b study. Lancet Oncol. 2025 Oct;26(10):1300-1311. doi: 10.1016/S1470-2045(25)00480-2. Epub 2025 Sep 8.","pmid":"40934933","type":"DERIVED"}],"start_date":{"date":"2024-06-05","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab","url":"https://clinicaltrials.gov/study/NCT06211036"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/dellphi-305-nct06211036"}